IceCure Medical Reports Record Sales for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 17 2026
0mins
Source: PRnewswire
- Record Sales Performance: IceCure Medical reported full-year sales of $3.4 million for 2025, up from $3.29 million in 2024, indicating strong growth momentum in the global market, particularly in low-risk breast cancer treatment.
- FDA Approval Boosts Market: Following FDA clearance for ProSense® in October 2025 for low-risk breast cancer, the company has seen significant commercial momentum in the U.S. market, which is expected to further drive procurement interest from hospitals and clinics.
- Clinical Research Expansion: IceCure plans to conduct FDA-approved post-marketing studies across 30 hybrid commercial-clinical sites, which will not only broaden its customer base but also provide critical data support for future market promotion.
- Improved Financial Position: Although gross profit decreased to $1.226 million with a gross margin of 36% in 2025, the net loss narrowed to $15.057 million, reflecting the company's positive progress in cost control and operational optimization.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICCM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICCM
Wall Street analysts forecast ICCM stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.235
Low
3.00
Averages
3.00
High
3.00
Current: 0.235
Low
3.00
Averages
3.00
High
3.00
About ICCM
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
IceCure Medical Receives 180-Day Nasdaq Compliance Extension
- Compliance Extension: IceCure Medical has received a 180-day extension from Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share for at least 10 consecutive business days, indicating the company meets all other listing criteria.
- Reverse Split Consideration: The company may consider a reverse share split if necessary to regain compliance, reflecting management's commitment to restoring the stock price and maintaining market presence.
- Initial Notification Context: IceCure first received notice from Nasdaq on November 12, 2025, for failing to meet the minimum bid price for 30 consecutive days, with the initial compliance period expiring on May 11, 2026, highlighting the compliance challenges faced by the company.
- Trading Continuity: Despite compliance issues, IceCure's shares will continue to trade on the Nasdaq Capital Market under the ticker “ICCM,” indicating the company's ongoing presence in the market.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Compliance Extension: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum $1.00 bid price requirement, demonstrating the company's commitment to maintaining its listing status.
- Price Requirement Not Met: Despite failing to maintain the minimum bid price over the previous 30 trading days, Nasdaq acknowledged the company's market value and compliance with other listing requirements, indicating potential for future compliance.
- Reverse Split Consideration: IceCure has indicated that it may consider a reverse share split if necessary to meet the price requirement, a strategy that could impact shareholder structure and market confidence.
- Ongoing Trading Status: The current notification has no immediate effect on the trading of the company's ordinary shares, which will continue to trade under the symbol “ICCM,” ensuring ongoing investor interest and confidence in the company's future.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Extended Compliance Period: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share, demonstrating the company's commitment to maintaining its listing status.
- Non-Compliance Notification: The company was initially notified in November 2025 that its shares did not meet the minimum bid price requirement, yet it successfully requested additional time, reflecting its accountability to shareholders and proactive management.
- Potential Reverse Split: IceCure indicated that it may consider a reverse share split to address the bid price deficiency, a strategy that could impact shareholder structure and market confidence, necessitating careful evaluation of its long-term implications.
- Ongoing Trading Status: The current notification has no immediate effect on the listing or trading of the company's ordinary shares, indicating stability in the market and continued liquidity for investors.
See More
IceCure Medical Reports Q1 2026 Financial Results
- Revenue Performance: IceCure Medical reported revenue of $911,000 for Q1 2026, indicating stability and potential growth in the market despite fluctuations compared to the previous year.
- Decrease in Sales and Marketing Expenses: Sales and marketing expenses for Q1 2026 were $1,068,000, down from $1,289,000 in Q1 2025, primarily due to reduced consulting fees related to regulatory submissions, showcasing the company's efforts in cost control.
- Increase in Administrative Expenses: General and administrative expenses rose to $1,263,000 in Q1 2026 from $922,000 in Q1 2025, largely driven by increased salary expenses due to fluctuations in the exchange rate between the U.S. dollar and Israeli shekel, reflecting operational cost pressures.
- Overall Operating Expenses Rise: Total operating expenses for Q1 2026 reached $4,542,000, up from $3,875,000 in Q1 2025, primarily due to increases in research and development and administrative expenses, despite a decrease in sales and marketing costs, indicating ongoing investment in R&D to drive future growth.
See More
IceCure Medical Reports Significant Growth in Q1 Performance
- Surge in Customer Accounts: As of Q1 2026, active customer accounts using ProSense® increased by 46% compared to pre-FDA clearance, indicating strong market demand and significant future sales potential.
- Significant Revenue Growth: Revenue for Q1 2026 reached $911,000, a 26% increase from $725,000 in Q1 2025, driven primarily by increased sales in the U.S., Canada, and Mexico, reflecting successful expansion in the North American market.
- Improved Gross Margin: The gross margin increased from 30% in 2025 to 32% in Q1 2026, with gross profit rising 35% to $295,000, indicating substantial progress in cost control and sales efficiency, thereby enhancing the company's financial health.
- Increased R&D Investment: R&D expenses for Q1 2026 were $2,211,000, up from $1,664,000 in 2025, primarily for the CHOICE study, demonstrating the company's ongoing commitment to technological innovation and market expansion.
See More
Breakthrough in Tumor Treatment with Cryoablation Technology
- Clinical Data Highlights: The ICESECRET trial demonstrated an 89.4% recurrence-free rate in patients with tumors ≤3 cm, with 83.9% remaining recurrence-free at a median follow-up of 4 years, indicating the efficacy and safety of cryoablation technology for small tumors.
- Independent Study Results: An independent breast cancer study reported no residual cancer at 6 and 12 months post-procedure, with 100% of patients reporting excellent cosmetic outcomes, further validating the application potential of ProSense® in early-stage breast cancer treatment.
- Technology Promotion and Training: The ECIO 2026 conference featured the first dedicated breast cryoablation course, attracting significant participation from physicians, highlighting the growing clinical recognition and interest in ProSense® for treating breast cancer, fibroadenomas, and kidney cancer.
- FDA Approval Driving Market: Following FDA clearance, global adoption and clinical interest in ProSense® are on the rise, marking cryoablation's potential as a minimally invasive alternative to surgery and its possible establishment as a standard treatment option.
See More
IceCure Medical Receives 180-Day Nasdaq Compliance Extension
- Compliance Extension: IceCure Medical has received a 180-day extension from Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share for at least 10 consecutive business days, indicating the company meets all other listing criteria.
- Reverse Split Consideration: The company may consider a reverse share split if necessary to regain compliance, reflecting management's commitment to restoring the stock price and maintaining market presence.
- Initial Notification Context: IceCure first received notice from Nasdaq on November 12, 2025, for failing to meet the minimum bid price for 30 consecutive days, with the initial compliance period expiring on May 11, 2026, highlighting the compliance challenges faced by the company.
- Trading Continuity: Despite compliance issues, IceCure's shares will continue to trade on the Nasdaq Capital Market under the ticker “ICCM,” indicating the company's ongoing presence in the market.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Compliance Extension: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum $1.00 bid price requirement, demonstrating the company's commitment to maintaining its listing status.
- Price Requirement Not Met: Despite failing to maintain the minimum bid price over the previous 30 trading days, Nasdaq acknowledged the company's market value and compliance with other listing requirements, indicating potential for future compliance.
- Reverse Split Consideration: IceCure has indicated that it may consider a reverse share split if necessary to meet the price requirement, a strategy that could impact shareholder structure and market confidence.
- Ongoing Trading Status: The current notification has no immediate effect on the trading of the company's ordinary shares, which will continue to trade under the symbol “ICCM,” ensuring ongoing investor interest and confidence in the company's future.
See More
IceCure Granted Extended Compliance Period by Nasdaq
- Extended Compliance Period: IceCure Medical has been granted an additional 180-day compliance period by Nasdaq until November 9, 2026, to meet the minimum bid price requirement of $1.00 per share, demonstrating the company's commitment to maintaining its listing status.
- Non-Compliance Notification: The company was initially notified in November 2025 that its shares did not meet the minimum bid price requirement, yet it successfully requested additional time, reflecting its accountability to shareholders and proactive management.
- Potential Reverse Split: IceCure indicated that it may consider a reverse share split to address the bid price deficiency, a strategy that could impact shareholder structure and market confidence, necessitating careful evaluation of its long-term implications.
- Ongoing Trading Status: The current notification has no immediate effect on the listing or trading of the company's ordinary shares, indicating stability in the market and continued liquidity for investors.
See More
IceCure Medical Reports Q1 2026 Financial Results
- Revenue Performance: IceCure Medical reported revenue of $911,000 for Q1 2026, indicating stability and potential growth in the market despite fluctuations compared to the previous year.
- Decrease in Sales and Marketing Expenses: Sales and marketing expenses for Q1 2026 were $1,068,000, down from $1,289,000 in Q1 2025, primarily due to reduced consulting fees related to regulatory submissions, showcasing the company's efforts in cost control.
- Increase in Administrative Expenses: General and administrative expenses rose to $1,263,000 in Q1 2026 from $922,000 in Q1 2025, largely driven by increased salary expenses due to fluctuations in the exchange rate between the U.S. dollar and Israeli shekel, reflecting operational cost pressures.
- Overall Operating Expenses Rise: Total operating expenses for Q1 2026 reached $4,542,000, up from $3,875,000 in Q1 2025, primarily due to increases in research and development and administrative expenses, despite a decrease in sales and marketing costs, indicating ongoing investment in R&D to drive future growth.
See More
IceCure Medical Reports Significant Growth in Q1 Performance
- Surge in Customer Accounts: As of Q1 2026, active customer accounts using ProSense® increased by 46% compared to pre-FDA clearance, indicating strong market demand and significant future sales potential.
- Significant Revenue Growth: Revenue for Q1 2026 reached $911,000, a 26% increase from $725,000 in Q1 2025, driven primarily by increased sales in the U.S., Canada, and Mexico, reflecting successful expansion in the North American market.
- Improved Gross Margin: The gross margin increased from 30% in 2025 to 32% in Q1 2026, with gross profit rising 35% to $295,000, indicating substantial progress in cost control and sales efficiency, thereby enhancing the company's financial health.
- Increased R&D Investment: R&D expenses for Q1 2026 were $2,211,000, up from $1,664,000 in 2025, primarily for the CHOICE study, demonstrating the company's ongoing commitment to technological innovation and market expansion.
See More
